Anti-Human κ Opioid Receptor Antibodies: Characterization of Site-Directed Neutralizing Antibodies Specific for a Peptide κR(33-52) Derived from the Predicted Amino Terminal Region of the Human κ Receptor

Robert R. Buchner, Shawn M. Vogen, Wolfgang Fischer, Marilyn L. Thoman, Sam D. Sanderson, Edward L. Morgan

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Site-directed polyclonal Abs specific for a synthetic peptide with sequence homology to the predicted N-terminal sequence of the human κ opioid receptor [anti-κR-(33-52)] are capable of binding to normal human cells and cell lines expressing mRNA specific for the human κ receptor. Flow cytometric analysis of 1) a neuronal cell line (NT2), 2) blood-denved CD14+ monocytes, 3) monocyte-like cell lines (U937 and THP 1), 4) blood-derived CD3+ T cells and a T cell line, and 5) human B cell lines bound anti-κR-(33-52) in a specific manner. Anti-κR-(33-52) was also found to specifically neutralize the immunosuppressive activities associated with the κR-selective agonist U50,488H. This antiserum was found to block U50,488H-mediated inhibition of 1) Staphylococcus aureus Cowen strain I-induced B and T lymphocyte proliferation, 2) PHA-induced T lymphocyte proliferation, and 3) S. aureus Cowen strain I-induced IgG production. However, this antiserum failed to neutralize μR-selective agonist (Tyr-D-Ala-Gly-NMe-Phe-Gly-ol)-mediated suppression of IgG synthesis. Finally, the κR-selective antagonist nor-binaltorphimine hydrochloride inhibits the binding of anti-κR-(33-52) to the U937 cell line. These results suggest that anti-κR-(33-52) specifically interacts with the human κR molecule. Studies conducted with anti-κR-(33-52) indicated that this antiserum effectively blocked U50,488H-mediated immunosuppression, but by itself did not enhance or suppress lymphocyte activation. These data suggest that anti-κR-(33-52) 1) does not interact with the effector binding site of the receptor, but sterically interferes with U50,488H binding to the receptor; and/or 2) the antiserum interacts with a secondary binding site that is important for ligand binding, but may not be involved in signal transduction.

Original languageEnglish (US)
Pages (from-to)1670-1680
Number of pages11
JournalJournal of Immunology
Volume158
Issue number4
StatePublished - Feb 15 1997

Fingerprint

Opioid Receptors
Neutralizing Antibodies
Cell Line
Antibodies
Immune Sera
T-Lymphocytes
Staphylococcus aureus
Monocytes
B-Lymphocytes
Immunoglobulin G
Binding Sites
Ala(2)-MePhe(4)-Gly(5)-enkephalin
U937 Cells
Immunosuppressive Agents
Lymphocyte Activation
Sequence Homology
Immunosuppression
R peptide
Signal Transduction
Ligands

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Anti-Human κ Opioid Receptor Antibodies : Characterization of Site-Directed Neutralizing Antibodies Specific for a Peptide κR(33-52) Derived from the Predicted Amino Terminal Region of the Human κ Receptor. / Buchner, Robert R.; Vogen, Shawn M.; Fischer, Wolfgang; Thoman, Marilyn L.; Sanderson, Sam D.; Morgan, Edward L.

In: Journal of Immunology, Vol. 158, No. 4, 15.02.1997, p. 1670-1680.

Research output: Contribution to journalArticle

Buchner, Robert R. ; Vogen, Shawn M. ; Fischer, Wolfgang ; Thoman, Marilyn L. ; Sanderson, Sam D. ; Morgan, Edward L. / Anti-Human κ Opioid Receptor Antibodies : Characterization of Site-Directed Neutralizing Antibodies Specific for a Peptide κR(33-52) Derived from the Predicted Amino Terminal Region of the Human κ Receptor. In: Journal of Immunology. 1997 ; Vol. 158, No. 4. pp. 1670-1680.
@article{8f7c5ba5de8146eda3d2520ad4155ea2,
title = "Anti-Human κ Opioid Receptor Antibodies: Characterization of Site-Directed Neutralizing Antibodies Specific for a Peptide κR(33-52) Derived from the Predicted Amino Terminal Region of the Human κ Receptor",
abstract = "Site-directed polyclonal Abs specific for a synthetic peptide with sequence homology to the predicted N-terminal sequence of the human κ opioid receptor [anti-κR-(33-52)] are capable of binding to normal human cells and cell lines expressing mRNA specific for the human κ receptor. Flow cytometric analysis of 1) a neuronal cell line (NT2), 2) blood-denved CD14+ monocytes, 3) monocyte-like cell lines (U937 and THP 1), 4) blood-derived CD3+ T cells and a T cell line, and 5) human B cell lines bound anti-κR-(33-52) in a specific manner. Anti-κR-(33-52) was also found to specifically neutralize the immunosuppressive activities associated with the κR-selective agonist U50,488H. This antiserum was found to block U50,488H-mediated inhibition of 1) Staphylococcus aureus Cowen strain I-induced B and T lymphocyte proliferation, 2) PHA-induced T lymphocyte proliferation, and 3) S. aureus Cowen strain I-induced IgG production. However, this antiserum failed to neutralize μR-selective agonist (Tyr-D-Ala-Gly-NMe-Phe-Gly-ol)-mediated suppression of IgG synthesis. Finally, the κR-selective antagonist nor-binaltorphimine hydrochloride inhibits the binding of anti-κR-(33-52) to the U937 cell line. These results suggest that anti-κR-(33-52) specifically interacts with the human κR molecule. Studies conducted with anti-κR-(33-52) indicated that this antiserum effectively blocked U50,488H-mediated immunosuppression, but by itself did not enhance or suppress lymphocyte activation. These data suggest that anti-κR-(33-52) 1) does not interact with the effector binding site of the receptor, but sterically interferes with U50,488H binding to the receptor; and/or 2) the antiserum interacts with a secondary binding site that is important for ligand binding, but may not be involved in signal transduction.",
author = "Buchner, {Robert R.} and Vogen, {Shawn M.} and Wolfgang Fischer and Thoman, {Marilyn L.} and Sanderson, {Sam D.} and Morgan, {Edward L.}",
year = "1997",
month = "2",
day = "15",
language = "English (US)",
volume = "158",
pages = "1670--1680",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "4",

}

TY - JOUR

T1 - Anti-Human κ Opioid Receptor Antibodies

T2 - Characterization of Site-Directed Neutralizing Antibodies Specific for a Peptide κR(33-52) Derived from the Predicted Amino Terminal Region of the Human κ Receptor

AU - Buchner, Robert R.

AU - Vogen, Shawn M.

AU - Fischer, Wolfgang

AU - Thoman, Marilyn L.

AU - Sanderson, Sam D.

AU - Morgan, Edward L.

PY - 1997/2/15

Y1 - 1997/2/15

N2 - Site-directed polyclonal Abs specific for a synthetic peptide with sequence homology to the predicted N-terminal sequence of the human κ opioid receptor [anti-κR-(33-52)] are capable of binding to normal human cells and cell lines expressing mRNA specific for the human κ receptor. Flow cytometric analysis of 1) a neuronal cell line (NT2), 2) blood-denved CD14+ monocytes, 3) monocyte-like cell lines (U937 and THP 1), 4) blood-derived CD3+ T cells and a T cell line, and 5) human B cell lines bound anti-κR-(33-52) in a specific manner. Anti-κR-(33-52) was also found to specifically neutralize the immunosuppressive activities associated with the κR-selective agonist U50,488H. This antiserum was found to block U50,488H-mediated inhibition of 1) Staphylococcus aureus Cowen strain I-induced B and T lymphocyte proliferation, 2) PHA-induced T lymphocyte proliferation, and 3) S. aureus Cowen strain I-induced IgG production. However, this antiserum failed to neutralize μR-selective agonist (Tyr-D-Ala-Gly-NMe-Phe-Gly-ol)-mediated suppression of IgG synthesis. Finally, the κR-selective antagonist nor-binaltorphimine hydrochloride inhibits the binding of anti-κR-(33-52) to the U937 cell line. These results suggest that anti-κR-(33-52) specifically interacts with the human κR molecule. Studies conducted with anti-κR-(33-52) indicated that this antiserum effectively blocked U50,488H-mediated immunosuppression, but by itself did not enhance or suppress lymphocyte activation. These data suggest that anti-κR-(33-52) 1) does not interact with the effector binding site of the receptor, but sterically interferes with U50,488H binding to the receptor; and/or 2) the antiserum interacts with a secondary binding site that is important for ligand binding, but may not be involved in signal transduction.

AB - Site-directed polyclonal Abs specific for a synthetic peptide with sequence homology to the predicted N-terminal sequence of the human κ opioid receptor [anti-κR-(33-52)] are capable of binding to normal human cells and cell lines expressing mRNA specific for the human κ receptor. Flow cytometric analysis of 1) a neuronal cell line (NT2), 2) blood-denved CD14+ monocytes, 3) monocyte-like cell lines (U937 and THP 1), 4) blood-derived CD3+ T cells and a T cell line, and 5) human B cell lines bound anti-κR-(33-52) in a specific manner. Anti-κR-(33-52) was also found to specifically neutralize the immunosuppressive activities associated with the κR-selective agonist U50,488H. This antiserum was found to block U50,488H-mediated inhibition of 1) Staphylococcus aureus Cowen strain I-induced B and T lymphocyte proliferation, 2) PHA-induced T lymphocyte proliferation, and 3) S. aureus Cowen strain I-induced IgG production. However, this antiserum failed to neutralize μR-selective agonist (Tyr-D-Ala-Gly-NMe-Phe-Gly-ol)-mediated suppression of IgG synthesis. Finally, the κR-selective antagonist nor-binaltorphimine hydrochloride inhibits the binding of anti-κR-(33-52) to the U937 cell line. These results suggest that anti-κR-(33-52) specifically interacts with the human κR molecule. Studies conducted with anti-κR-(33-52) indicated that this antiserum effectively blocked U50,488H-mediated immunosuppression, but by itself did not enhance or suppress lymphocyte activation. These data suggest that anti-κR-(33-52) 1) does not interact with the effector binding site of the receptor, but sterically interferes with U50,488H binding to the receptor; and/or 2) the antiserum interacts with a secondary binding site that is important for ligand binding, but may not be involved in signal transduction.

UR - http://www.scopus.com/inward/record.url?scp=0031568393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031568393&partnerID=8YFLogxK

M3 - Article

C2 - 9029103

AN - SCOPUS:0031568393

VL - 158

SP - 1670

EP - 1680

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 4

ER -